PREVENCIJA SPINALNOG DISRAFIZMA PRIMENOM FOLNE KISELINE
DOI:
https://doi.org/10.46793/PP180218013CKljučne reči:
Folna kiselina, Spina bifida, prevencijaApstrakt
Uvod: Folna kiselina je neophodna za funkcionisanje svake ćelije i za izgradnju svih novih ćelija, za konverziju nekih aminokiselina, ima i važnu ulogu u eritropoezi. Značajna je za normalan razvoj neuralne cevi i zbog toga je veoma značajna za normalan razvoj ploda. Prenatalna primena folne kiseline, u primarnoj i sekundarnoj prevenciji defekata neuralne cevi, poznata je unazad nekoliko decenija. U radu prikazujemo poznate dokaze o dejstvu folne kiseline na prevenciju nastanka defekata neuralne cevi, ali i na pravilnu suplementaciju u trudnoći, te mogućnost dejstva suplementacije folnom kiselinom na druge ishode trudnoće.
Metodologija: Istraživanje je sprovedeno u Opštini Zaječar. U porodilištu Zdravstvenog centra Zaječar, u periodu od 1987. do 2015. godine rođeno je 22 145. dece. Od tog broja 13-ro dece sa defektom neuralne cevi ili 0,587/1000 živorođene dece. Majke čija deca su imala Spinu bifidu nisu koristile u toku trudnoće folnu kiselinu. Od 2012. godine, kada je uvedena primena folne kiseline, nije rodjeno nijedno dete sa ovom kongenitalnom anomalijom.
Rezultati: Rezultati istraživanja govore da je broj dece sa defektom neuralne cevi u padu, nakon primene folne kiseline.
Zaključak: Pokazan je značaj primene folne kiseline kod trudnica sa ciljem prevencije urodjenih anomalija neuralne cevi.
Reference
Grosse SD, Berry RJ, Tilford JM, Kucik JE, Waitzman NJ. Retrospective assessment of cost savings from prevention: Folic acid fortification and spina bifida in the U.S. American Journal of Preventive Medicine. January 2016.
Mertens P. Spina Bifida and primary prevention. Orphanet Journal of Rare Diseases 20127(Suppl 2): A18.
Osterhues A, Ali NS, Michels KB. The role of folic acid fortification in neural tube defects: a review. Crit. Rev. Food Sci. Nutr. 2013; 53, 1180–1190.
Patel N, Viguera AC, Baldessarini RJ. Mood. Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary. J Clin Psychopharmacol. 2018; Feb 38 (1):7-10.
Ricks, D. J. et al. Peru's national folic acid fortification program and its effect on neural tube defects in Lima. Rev. Panam. Salud Pubica 2012; 32, 391–398.
Systematic Reviews. Folic acid supplements before conception and in early pregnancy (up to 12 weeks) for the prevention of birth defects. 2015, Issue 12.
American Pregnancy Association 2017. Maternal Serum Alpha-Fetoprotein Screening (MSAFP) . 2016 Sep 2.
Schechter MS, Liu T, Soe M, et al. Sociodemographic Attributes and Spina Bifida Outcomes. Pediatrics. 2015 April; 135(4).
Saadai P, Farmer DL. Fetal surgery for myelomeningocele. Clinics in Perinatology 2012; 39 (2), 279–288.
American Association for Clinical Chemistry. 2017; Glossary: Spina Bifida.
National Center for Advancing Translational Sciences/Genetic and Rare Diseases. U.S. Department of Health and Human Services; Neural Tube Defects. 2017.
Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol 2013;12: 799-810.
Oakeshott P, Hunt GM, Poulton A. et al. Open spina bifida: birth findings predict long-term outcome. Arch Dis Child 2012; 97, 474–476.
Juriloff DM, Harris M J. Hypothesis: the female excess in cranial neural tube defects reflects an epigenetic drag of the inactivating X chromosome on the molecular mechanisms of neural fold elevation. Birth Defects Res Clin Mol Teratol 2012; 94, 849–855.
Agopian AJ, Tinker SC, Lupo PJ, et al. Proportion of neural tube defects attributable to known risk factors. Birth Defects Res Clin Mol Teratol 2013; 97, 42–46.
Bahlmann F. et al. Cranial and cerebral signs in the diagnosis of spina bifida between 18 and 22 weeks of gestation: a German multicenter study. Prenat Diag 2014; 35, 228–235.
Adzick NS. Fetal surgery for myelomeningocele: trials and tribulations. Isabella Forshall Lecture. J Pediatr Surg 2012; 47, 273–281.
Murray CB et al. A longitudinal examination of health-related quality of life in children and adolescents with spina bifida. J Pediatr Psychol 2014.
Wilde J J, Petersen JR, Niswander L. Genetic, epigenetic, and environmental contributions to neural tube closure. Annu Rev Genet 2014; 48, 583–611.
Stubberud J, Langenbahn D, Levine B, et al. Emotional health and coping in spina bifida after goal management training: a randomized controlled trial. Rehabil Psychol 2014; 60, 1–16.
EUROCAT.Special Report: Prevention of Neural Tube Defects by Periconpceptional Folic Acid Supplementation in Europe. 2009
